FMP

FMP

Enter

CRL - Charles River Labora...

photo-url-https://images.financialmodelingprep.com/symbol/CRL.png

Charles River Laboratories International, Inc.

CRL

NYSE

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

171.04 USD

4.11 (2.4%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

2.92B

3.54B

3.98B

4.13B

4.05B

4.41B

4.8B

5.22B

5.68B

6.18B

Revenue %

-

21.08

12.31

3.86

-1.92

8.83

8.83

8.83

8.83

Ebitda

759.15M

854.29M

1.04B

1.03B

581.14M

1.02B

1.11B

1.21B

1.31B

1.43B

Ebitda %

25.96

24.13

26.05

24.99

14.35

23.1

23.1

23.1

23.1

Ebit

524.22M

588.75M

731.99M

717.99M

219.4M

667.97M

726.95M

791.14M

861M

937.03M

Ebit %

17.93

16.63

18.41

17.39

5.42

15.15

15.15

15.15

15.15

Depreciation

234.92M

265.54M

303.87M

314.12M

361.74M

350.11M

381.03M

414.68M

451.29M

491.14M

Depreciation %

8.03

7.5

7.64

7.61

8.93

7.94

7.94

7.94

7.94

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

228.42M

241.21M

233.91M

276.77M

194.61M

282.23M

307.15M

334.28M

363.8M

395.92M

Total Cash %

7.81

6.81

5.88

6.7

4.81

6.4

6.4

6.4

6.4

Receivables

617.74M

642.88M

752.39M

780.38M

720.91M

836.64M

910.52M

990.92M

1.08B

1.17B

Receivables %

21.13

18.16

18.92

18.9

17.8

18.98

18.98

18.98

18.98

Inventories

185.69M

199.15M

255.81M

380.26M

278.54M

304.09M

330.94M

360.17M

391.97M

426.59M

Inventories %

6.35

5.63

6.43

9.21

6.88

6.9

6.9

6.9

6.9

Payable

122.47M

198.13M

205.91M

168.94M

140.34M

198.52M

216.05M

235.13M

255.9M

278.49M

Payable %

4.19

5.6

5.18

4.09

3.47

4.5

4.5

4.5

4.5

Cap Ex

-166.56M

-228.77M

-324.73M

-318.53M

-232.97M

-297.88M

-324.19M

-352.81M

-383.97M

-417.88M

Cap Ex %

-5.7

-6.46

-8.17

-7.71

-5.75

-6.76

-6.76

-6.76

-6.76

Weighted Average Cost Of Capital

Price

171.04

Beta

Diluted Shares Outstanding

51.63M

Costof Debt

4.64

Tax Rate

After Tax Cost Of Debt

1.11

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

2.72B

Total Equity

8.83B

Total Capital

11.55B

Debt Weighting

23.58

Equity Weighting

76.42

Wacc

9.11

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

2.92B

3.54B

3.98B

4.13B

4.05B

4.41B

4.8B

5.22B

5.68B

6.18B

Ebitda

759.15M

854.29M

1.04B

1.03B

581.14M

1.02B

1.11B

1.21B

1.31B

1.43B

Ebit

524.22M

588.75M

731.99M

717.99M

219.4M

667.97M

726.95M

791.14M

861M

937.03M

Tax Rate

76.16

76.16

76.16

76.16

76.16

76.16

76.16

76.16

76.16

76.16

Ebiat

427.13M

478.86M

571.3M

586.25M

52.32M

462.71M

503.57M

548.04M

596.43M

649.1M

Depreciation

234.92M

265.54M

303.87M

314.12M

361.74M

350.11M

381.03M

414.68M

451.29M

491.14M

Receivables

617.74M

642.88M

752.39M

780.38M

720.91M

836.64M

910.52M

990.92M

1.08B

1.17B

Inventories

185.69M

199.15M

255.81M

380.26M

278.54M

304.09M

330.94M

360.17M

391.97M

426.59M

Payable

122.47M

198.13M

205.91M

168.94M

140.34M

198.52M

216.05M

235.13M

255.9M

278.49M

Cap Ex

-166.56M

-228.77M

-324.73M

-318.53M

-232.97M

-297.88M

-324.19M

-352.81M

-383.97M

-417.88M

Ufcf

-185.47M

552.69M

392.05M

392.43M

313.67M

431.85M

477.21M

519.35M

565.21M

615.12M

Wacc

9.11

9.11

9.11

9.11

9.11

Pv Ufcf

395.8M

400.85M

399.82M

398.8M

397.77M

Sum Pv Ufcf

1.99B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

9.11

Free Cash Flow T1

633.57M

Terminal Value

10.38B

Present Terminal Value

6.71B

Intrinsic Value

Enterprise Value

8.7B

Net Debt

2.53B

Equity Value

6.17B

Diluted Shares Outstanding

51.63M

Equity Value Per Share

119.6

Projected DCF

119.6 -0.43%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep